PRESS RELEASE published on 01/28/2026 at 07:43, 9 months 4 days ago Informations privilégiées / Autres communiqués Sensorion annonce un financement de 60 millions d’euros avec Sanofi et d'autres investisseurs pour développer ses thérapies géniques. Trésorerie prévue jusqu'à mi-2027 Financement Trésorerie Thérapie Génique Sanofi Sensorion
PRESS RELEASE published on 01/28/2026 at 07:43, 9 months 4 days ago Inside Information / Other news releases Sensorion announces €60 million financing with a €20M strategic investment from Sanofi and support from global healthcare specialists to advance genetic medicine pipeline. Cash runway extended until H1 2027 Financing Sanofi Sensorion Genetic Medicine Healthcare Specialists
BRIEF published on 12/19/2025 at 07:35, 10 months 13 days ago Sensorion présentera ses services lors de la conférence JP Morgan Healthcare. Biotechnologie Thérapie Génique JP Morgan Perte Auditive SENS-401
BRIEF published on 12/19/2025 at 07:35, 10 months 13 days ago Sensorion to Present at J.P. Morgan Healthcare Conference Biotechnology Gene Therapy J.P. Morgan Hearing Loss SENS-401
PRESS RELEASE published on 12/19/2025 at 07:30, 10 months 13 days ago Informations privilégiées / Autres communiqués Sensorion annonce sa participation à la 44ème conférence annuelle J.P. Morgan Healthcare Conference à San Francisco du 12 au 15 janvier 2026 pour présenter ses avancées en thérapies auditives Biotechnologie Conference J.P. Morgan Sensorion Thérapies Auditives
PRESS RELEASE published on 12/19/2025 at 07:30, 10 months 13 days ago Inside Information / Other news releases Sensorion to present at 44th Annual J.P. Morgan Healthcare Conference with focus on novel therapies for hearing loss disorders. CEO Nawal Ouzren to lead presentation Biotechnology Sensorion Hearing Loss Disorders J.P. Morgan Healthcare Conference Thérapies
BRIEF published on 09/17/2025 at 07:35, 1 year 1 month ago Sensorion annonce ses résultats semestriels 2025 Financement Thérapie Génique SENS-401 SENS-501 Résultats 2025
BRIEF published on 09/17/2025 at 07:35, 1 year 1 month ago Sensorion announces its 2025 half-year results Funding Gene Therapy SENS-401 SENS-501 2025 Results
PRESS RELEASE published on 09/17/2025 at 07:30, 1 year 1 month ago Informations privilégiées / Communiqué sur comptes, résultats Sensorion présente ses résultats du premier semestre 2025, activités de thérapie génique SENS-501, GJB2-GT et SENS-401, annonce dépôts réglementaires et études cliniques en cours Résultats Thérapie Génique Études Cliniques Dépôts Réglementaires Sensorion
PRESS RELEASE published on 09/17/2025 at 07:30, 1 year 1 month ago Inside Information / News release on accounts, results Sensorion reports 2025 half-year results, corporate update, and availability of half-year report. Progress in gene therapy programs for hearing loss disorders discussed Clinical Trials Gene Therapy Sensorion Hearing Loss Disorders 2025 Half-Year Results
Published on 10/30/2026 at 23:35, 2 days 7 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days 7 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 2 days 11 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 15 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/02/2026 at 06:00, 50 minutes ago Wujiang Marks 90 Years Since Fei Xiaotong's Jiangcun Field Study
Published on 11/01/2026 at 10:35, 20 hours 15 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 1 day 1 hour ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 1 day 14 hours ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 2 days 8 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 2 days 7 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 23:00, 2 days 7 hours ago Biophytis publie les résultats du premier semestre 2026 et fait le point sur sa stratégie
